We seek to accelerate and improve drug development programs via partnerships / collaborations for the benefit of patients and to create value for our investors.
We are currently seeking development partners / collaborators for the following Clover programs:
-Trimer-Tag© Vaccine Programs
-HIV/AIDS Vaccine (gp120-Trimer)
-Quadrivalent Influenza Vaccine (HA-Trimer)
-RSV Vaccine (F Antigen-Trimer)
-Other infectious diseases
-Ex-China regional rights for current programs
-Use of Trimer-Tag© to create trimeric antigens for monoclonal antibody (mAb) production or screening
-Use of Trimer-Tag© to develop trimeric fusion protein drugs for targets not currently being developed by Clover
If you would like additional information on partnering with Clover, we encourage you to contact us.